Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced <i>BRAF</i>-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.

Of note, even in the group resembling those for whom dabrafenib/trametinib is purported to do best (those with performance status 0, normal LDH, and lower stage, perhaps a surrogate for < 3 disease sites), starting with nivolumab/ipilimumab showed a trend for improved OS.

also in 53,322 other papers